Bayer Agrees to $7.25 Billion Proposed Settlement Over Thousands of Roundup Cancer Lawsuits

In a significant development for Bayer, the company announced on February 17, 2026, that it has agreed to a proposed settlement totaling $7.25 billion to address thousands of lawsuits filed by individuals claiming that exposure to Roundup, a glyphosate-based herbicide, has led to serious health issues, including non-Hodgkin lymphoma.

The settlement aims to resolve approximately 125,000 claims lodged against Bayer following its acquisition of Monsanto, the original manufacturer of Roundup. Plaintiffs have contended that the company failed to warn consumers adequately about the potential cancer risks associated with the herbicide.

This proposed settlement marks a major effort by Bayer to move beyond the extensive litigation that has plagued the company since the acquisition. Bayer previously faced a series of high-profile trials and significant jury awards, raising concerns over the long-term viability of its product lines containing glyphosate.

The settlement terms, which still require approval from the courts, would allocate significant funds for cancer research, medical monitoring for affected individuals, and compensation for plaintiffs. Bayer has stated that part of the settlement will be used to support programs aimed at promoting safe agricultural practices and protecting public health.

While the proposed settlement is considered a step towards closure for many affected individuals, the controversy around Roundup and glyphosate continues to spark debates over regulatory practices, product safety, and corporate responsibility. Bayer is poised to implement enhanced safety measures and public awareness campaigns as it strives to regain consumer trust.

As the situation develops, both Bayer and legal representatives for the plaintiffs remain focused on finalizing the settlement and addressing the broader implications of glyphosate usage in agriculture and beyond. The proposal highlights the ongoing challenges faced by the agricultural industry in balancing product efficacy with health safety concerns.